Indication
Age-Related Macular Degeneration
The Age-Related Macular Degeneration pipeline: 32 tracked drugs, 9 approved for this indication.
9 approved / phase 415 Phase 31 Phase 2/32 Phase 23 Phase 1/22 preclinical / unstaged
Compare the share prices of listed companies in Age-Related Macular Degeneration →
Total attributable cost
$486.2B
$24,520/patient
Drug spend
$9.7B
$490/patient
2% of total cost is drugs
All stages and forms (US estimate) · US